Format

Send to

Choose Destination
See comment in PubMed Commons below
Gene. 2014 Oct 15;550(1):40-5. doi: 10.1016/j.gene.2014.08.011. Epub 2014 Aug 7.

The potential impact of P53 and APO-1 genetic polymorphisms on hepatitis C genotype 4a susceptibility.

Author information

1
Hormones Department, Medical Research Division, National Research Centre, Cairo, Egypt.
2
Hormones Department, Medical Research Division, National Research Centre, Cairo, Egypt. Electronic address: ahmedchemia87@yahoo.com.
3
Chemistry Department, Biochemistry Specialty, Faculty of Science, Cairo University, Egypt.
4
Internal Medicine Department, Medical Research Division, National Research Centre, Cairo, Egypt.
5
Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Cairo University, Egypt.

Abstract

The hepatitis C virus (HCV), the main cause of morbidity and mortality, is endemic worldwide. HCV causes cirrhosis and other complications that often lead to death. HCV is most common in underdeveloped nations, with the highest prevalence rates in Egypt. Tumor suppressor gene (P53) induces the expression of apoptotic antigen-1 gene (APO-1) by binding to its promoter for mediating apoptosis; an important mechanism for limiting viral replication. This study aims at investigating the impact of P53 72 Arg/Pro and APO-1 -670 A/G polymorphisms on HCV genotype 4a susceptibility. Two hundred and forty volunteers were enrolled in this study and divided into two major groups; 160 HCV infected patient group and 80 healthy control group. HCV patients were classified according to Metavir scoring system into two subgroups; 72 patients in F0/1-HCV subgroup (patients with no or mild fibrotic stages) and 38 patients in F3/4-HCV subgroup (patients with advanced fibrotic stages). Quantification of HCV-RNA by qRT-PCR and fibrotic scores as well as genotyping of HCV-RNA, P53 at 72 Arg/Pro, and APO-1 at -670 A/G were performed for all subjects. It was resulted that F0/1-HCV patients have significant differences of P53 at 72 (Pro/Pro and Arg/Arg) genotypes and dominant/recessive genetic models as well as APO-1 -670 A/A genotype and dominant genetic model as compared to F3/4-HCV patients. Moreover, HCV patients have significant differences of P53 at 72 (Pro/Pro) genotype and recessive genetic model as well as APO-1 -670 A/A genotype and dominant genetic model as compared to those of healthy individuals. Finally, it was concluded that P53 rs 1042522 (Pro/Pro and Arg/Arg) genotypes and APO-1 rs 1800682 A/A genotype may be potentially used as sensitive genetic markers for HCV genotype 4a susceptibility.

KEYWORDS:

APO-1 −670A/G; HCV genotype 4a; P53 Arg72Pro; SNPs

PMID:
25108128
DOI:
10.1016/j.gene.2014.08.011
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center